Comparison of Pharmacovigilance and Herbovigilance Regulatory Guidelines at the Global Level 
Kumari Arpana Kajal  a, * 
a Lovely Professional University, India	
A R T I C L E  I N F O  	A B S T R A C T  

Received 08 March 2023;
Revised 26 April 2023;
Accepted 20 May 2023.
	Pharmacovigilance is the most cutting-edge technology in the medical field, the most advanced technology in the medical field. It focuses on identifying, evaluating, analyzing, and preventing pharmacological side effects based on identification evaluation analysis and prevention of pharmacological side effects based on long-term and short-term drug exposure. Through the monitoring of drug safety, pharmacovigilance science seeks to enhance patient safety and population welfare.
Every nation has regulatory organizations examining case reporting data and examines case reporting data and actual drug-related toxicological concerns. All adverse international unfavorable events in the country are centered at Uppsala Monitoring Centre (UMC). UMC determines judgments based on their investigation connected to numerous aspects of every case report, from Herbovigilance to the Pharmacovigilance drug program. The World Health Organization (WHO) was assisted by UMC when making worldwide decision-making on a global scale. 

Keywords:
Pharmaceutical, Drug Safety, Authority, Surveillance	
An official publication of the Global Pharmacovigilance Society. 

Introduction: 
Medical research attained a new milestone to ensure stability and efficiency; the World Health Organization developed PV, with the expansion of patient safety awareness an absolute priority (PV). The field of science and medicine known as PV deals with the identification, evaluation, and significant action required to preserve the post-market integrity of pharmaceutical drugs. PV serves as an essential important public health device that simultaneously reduces liability and increases the advantages of pharmaceutical goods and services (Garashi et al., 2022). PV is described as "the science and practices associated with the detection, diagnosis, evaluation, and mitigation of adverse effects or any other drug-related problem" by the World Health Organization (WHO)(Garashi et al., 2022).  In every nation, PV regulates the check and balance between the benefits and adverse events related to drug products and the population frequently used these. Whenever a drug launches in the market for the health sector it undergoes various steps of preclinical and clinical trials, to ensure the maximum efficacy with the least toxic effect on humans.  In the past Healthcare, the system did not recognize the bottom-line nature of post-marketing Adverse Drug Reactions (ADRs) and not have accepted adequate knowledge and credentials to perceive and competently record the ADRs (Garashi et al., 2022). Every government's PV controls the balance between positive and negative effects associated with and negative ones associated with drug products and the populace who use them often. 
Pharmacovigilance
PV represents the awareness and action strategy for adverse drug events and, more considerably, causality preventive measures from the worldwide health authorities. The Uppsala Monitoring Centre (UMC) assisted the World Health Organization in quick way reporting, signal detection, case appraisal, and immediate correction (WHO). Accept the medication's self-life statistics, health consequences, complications, and severe events based on cases in the typical community. Patients' drug-related constraints and blue devils are reduced due to PV's acceptance of post-marketing (i.e., real-world) complying with drug assuring and effectiveness evidence (Garashi et al., 2022). A unique form is known as the YC is used to get a spontaneous reporting of medication toxicity (Fornasier et al., 2018). The YC system was created to identify warning signs of potential issues that call for more research (Hinder et al., 2022). ” After presenting a product to the market, it represents the most effective technique to analyze medications or biologics. The program was moved to UMC in Sweden in 1978.  However, the UMC's current objective is to "safeguard patients," which drives the research and development of patient safety and PV-related devices and methods that support worldwide PV (Hinder et al., 2022). [Fig 1].


Fig 1: History of Evolution of Pharmacovigilance
History and Their Regulation
PV combines many components to order to maximize therapeutic safety and efficacy through the numerous regulatory agencies on a global scale. Every single phase plays a critical part in risk assessment and determination of the severity of the drug product on the market, from population involvement to technological intervention, administration to regulations' standards, case reporting to etiology evaluation. Broadly, it lowers the risk related to the medicine and handles medication satisfaction [Fig  2]. 
The background of PV was brought to mind around 170 years ago, on January 29, 1848, when Hannah Greener, a young girl from the northern area of England, passed away after receiving chloroform anesthesia before the removal of inflamed toenails (Fornasier et al., 2018). The goals of this association were to increase all aspects of safer and responsible drug consumption and to popularize PV. The European Medicines Agency (EMA) was founded in 1995 (Fornasier et al., 2018).

Fig: 2. Elements of the Pharmacovigilance
Herbovigilance
The ancient and most reliable medical treatment utilized by humanity is herbal medicine, which can be made from either the complete plant or a component for therapeutic purposes. The use of herbal preparations as medicinal agents is widely accepted. Examples include hepatoprotectives, anti-arthritics, beta-blockers- blockers, cough suppressants, potentiates, and memory boosters (Wal et al., 2011).  The WHO has praised the gradual addition of national PV centers and the pharmaceutical supervisory, advisory board, among others, to the guidelines (WHO, 2004). The common misconception about herbal remedies is they are impervious, allowing patients to consume them cautiously without needing them on their own or needing their own without needing them on their own or needing a doctor's prescription (Shetti et al., 2011). This may be due to the increase in the use of unusual medicines, such as herbal remedies, which may present specific toxicology issues, whether taken independently or in conjunction with certain other medications whether taken alone or in conjunction with other medicines, may raise toxicological problems toxicological specific problems toxicological issues (Wal et al., 2011). Herbal remedies are regularly taken in conjunction with other pharmaceuticals, so it's essential to comprehend how they work together and watch for any adverse effects (WHO, 2004). Herbal medications typically have a variety of constituents, and it is not always possible to identify all  (Shetti et al., 2011). [Fig 3]


Fig: 3 History of Evolution of Herbovigilance

Regulatory authority at the global level
After one drug is introduced to the market, numerous regulations worldwide all over the world examine every case report to determine its seriousness and take appropriate action. This is done to ensure drug safety and effective surveillance. 


Table: 1 Regulatory Body in Different Countries 
Sl. No	International/ Country Specific	Name of the Regulatory Bodies
1	International 	World Health Organization (WHO)
2	International	Uppsala Monitoring Centre (UMC)
3	India	Central Drugs Standard Control Organization (CDSCO)
4	New Zealand	Medicines and medical device safety authority  (Medsafe)
5	USA	Food and Drug Administration (FDA)
6	Canada	Health Canada
7	Europe	European Medicine Agencies (EMA)
8	Japan	Ministry of Health, Labour, and Welfare (MHLW)
9	Australia	Therapeutic Goods Administration (TGA)
10	UK	Medicines and Healthcare Products Regulatory Agency (MHRA)


Table 2:- Comparison of Pharmacovigilance at the Global Level

Brief About The Pharmacovigilance Across The Globe
India
India is a PV-growing nation with a significant influence on the developing development of the country's healthcare sector (Biswas et al., 2007). Underneath the National Pharmacovigilance Program (NPV) in 2010, the Central Drug Standard Control Organization (CDSCO) in India managers in charge of managing the PV works.  Adverse occurrences must be reported within 24 hours of their event to healthcare practitioners (verbally or in writing), as well as to any commercial or federal reporting sources of, of reporting, such as (toll-free No, Website, email, or postal) provided by the World Health Organization (UMC) (Biswas et al., 2007). The tools (Vigiflow) are made available by the World Health Organization (UMC) to all licensed healthcare professionals to enable them to report instances of various illnesses in-depth.

Pakistan
The Pakistan National Pharmacovigilance Centre (PNPC) has been established to oversee the security of the country's medicinal appetites under the watchful eye of the Drug Governing Authority of Pakistan (DRAP) (WHO, 2004). Following that, PPCs and PHPs should acknowledge serious ADR/AE reports to PNPC within 15 calendar days, and non-serious ADR/AE reports to PNPC before 30. PNPC DRAP will handle all clarification with WHO-UMC and WHO headquarters clarification with WHO-UMC, and PNPC DRAP will deal with WHO headquarters will be dealt with by PNPC DRAP. Through media releases, direct communications with medical practitioners, a website, a newsletter, and advisories regarding updates on adverse outcomes and health-related information, the government keeps the general population updated. 
Srilanka
The National Medicines Regulatory Authority Act Number allows PV in Sri Lanka in Sri Lanka as permitted by the National Medicines Regulatory Authority Act Number. 05 May 2015, as well as its guidelines and protocol (Fornasier et al., 2018). The leading information source in Sri Lanka's PV system is spontaneous reporting. Medical professionals can give ADR reports to the PV division complaints could be given to a PV division by professionals, particularly physicians, dental, pharmacy, and nursing. Within 24 hours, reports of significant adverse occurrences must be made (WHO, 2002). Negative events must be reported before seven calendar days. The Sri Lankan government offers all channels for unscheduled case reporting, including WebPages, faxes, casualty rate lines, and regular official pronouncements for health- and awareness-related notifications.  
Nepal
The National Drug Regulatory Authority of Nepal, which was founded in 1995, oversees in 1995, overseeing charge of overseeing the development of PV and medical security (Fornasier et al., 2018). The future of biopharmaceutical quality and reliability in Nepal has several worldwide components. The government purposefully makes the medical system easier, yet insurance reporting still requires improvement. The situation must be reported to the medical staff within 24 hours of the incident. Within seven calendar days, representatives of the government must react to the same. The government constantly connects with the populace via radios, vocational and educational programs, newspapers, and other media.  
Bangladesh
The Department of the Directorate General of Drug Administration (DGDA), founded in 1996 and decommissioned in 2013, is responsible for the Bangladesh PV program (Fornasier et al., 2018). Within 24 to 28 hours of an ADR incidence, cases are reported via government-recognized faxes, emails, toll-free numbers, and webpage. The case writing response has a seven-day deadline (Garashi et al., 2022). Additionally, the government uses TV commercials, websites, newsletters, telecommunications, and releases to reach the public (WHO, 1973). The ministry often hosted seminars, training workshops, and Email Addresses for pleasant contact regarding medical problems to the population and both domestic and international medical and governmental authorities to facilitate monitoring and medical collaboration.


Newzealand
Under the MedSafe-Medicines and Medical Devices Safety/Device, created around 1998, the PV Center of New Zealand has authorization (Garashi et al., 2022). In New Zealand, the reporting procedure is carried out nationwide using phones, e-mail, and websites. Twenty-eight hours after the adverse event occurs is the deadline for reporting it. The response time for this sort of ADRs form is seven consecutive weekdays. The government offers the public several communication ways, including news articles, bulletins, and online networks. The worldwide healthcare organization's reporting website is called Vigiflow, and its database-gathering program is called Caveat. 
Brazil
The Brazilian National Health Monitoring Agency (Anvisa), founded in 1999, created and supervised the medication monitoring program in that country (Garashi et al., 2022). During 72 hours of ADRs, consumers report incidents through written documents, phone calls, emails, and websites. Within ten days, the ADRs forms' reporting requirements should be addressed (WHO, 2002). The government informs, updates, and alerts the populace through conferences, educational programs, webinars, advertisements, social media, newsletters, conferences, educational programs, webinars, promotions, social media, and newsletters, the government informs, educates, and alerts populace. Applications help report the situation in detail, including Vigiflow and VigiMed (demographic information, drug information, medical history, drug-drug interaction, and many more). 
Europe
The Agency may be relied upon to create and manage Eduravigilance, a platform for monitoring and evaluating data on reported hazardous responses of drugs approved in the European Economic Area (EEA). The EMA has contracted with several organizations to oversee research initiatives gathering and exemplifying actual data from clinical practice. This advice keeps an eye on the safety and efficacy of medications.
The introduction of the PV constitution in July 2012 marked the finest fortunate event for the proper use of medicinal medications within the European Union (EU) since 1995 (Fornasier et al., 2018). The Organization significantly impacts how actions related to, Endorsing, and evaluating safety surveillance, pharmaceuticals, and a significant impact on how activities associated with supporting and assessing safety surveillance, drugs, including medical equipment, are coordinated all over the network (WHO, 2000).


United States
After the disaster of the life-threatening drug thalidomide, the United States made history in the field of PV by evolving the entire system. In the United States, the Food and Drug Administration (FDA), founded in 1906, is the PV's reporting authority (Harmark et al., 2008). In the US, ADRs can be notified by telephone, telegraph, mail, online reporting to medical experts, or the government's official website the authorities (Harmark et al., 2008). The government regularly disseminates information via conferences, the FDA webpage, official statements, and magazines. Public health care workers can access VigiFlow or VigiBase, reporting databases the WHO-UMC provides, to help with the exact reporting process (WHO, 1973). To ensure health protection and safety in the nation, US nations also exchange their internet site, toll-free number, and e-mail address. 
South Africa
PV throughout South Africa has developed into an all-encompassing scientific method that links the pre-marketing and post-marketing processes of drug development and assesses the legal responsibility and health promotion burden of medicinal products to use more comprehensive data sources like Registry data and prospective studies, in line with global advancement (van Grootheest et al., 2004). The nation's post-marketing surveillance is under the control of the National Adverse Drug Monitoring, which was founded in 2017 (van Grootheest et al., 2004). The international regulatory organizations Vigiflow and Vigibase provide access to their database for case filing to collect and input necessary data in an error-accessible method. 
Namibia
The Namibia Medicines Regulatory Council, founded in 2003, oversees Namibia's PV program (WHO, 1973). Adverse events must be documented to the patient before two days, and the form must be completed and returned beyond 15 days. Governmental resources spread community awareness of global medical problems through bulletins, official statements, and news releases (WHO, 1973). The most popular platform for adverse incident tracking and data processing across the country is VigiFlow, followed by VigiBase (Garashi et al., 2022). 
Canada
The responsibility for biopharmaceutical monitoring in Canada is shared between territorial governments, governmental departments, and regional health departments (Health Canada, 2006). In 1993, Health Canada developed the Canada PV Project (Health Canada, 2009a). Case reports may be submitted by the internet website, email, toll-free number, or verbally with medical professionals. The most significant time frame for reporting cases is 48 hours after the event, and the kind of application needs to have a response in 15 days (Health Canada, 2006). 
Herbovigilance
India
India has been following up the traditional system of medicine since the 6000 BC century commonly known as Ayurveda (Skalli et al., 2022).  It is the first traditional method where natural sources such as herbals are used in the form of crude extract in the purest form. It's a myth that herbal or natural products are harmless and 100% safe. In India AYUSH (Ministry of Health) is the governmental body that regulates the herbal pharmaceutical across the nation (Farah et al., 2000). AYUSH take care of the formulation of herbal medicaments and their pre-marketing testing according to the world standard provided by the WHO (Wal et al., 2011). In India, there were around 500 AYUSH junior campuses with access potentiality of over 25,000 in 2013 (Shetti et al., 2011). 
Pakistan
Pakistan, a relatively low nation in the western part of the Indian Subcontinent, is home to more than 207 million people, making it the sixth most populous country in the world  3.5% and 43.4 %, respectively, of the population are over age 65 (Gardiner et al., 2008).  Pakistan has 647 pharmacologically active production licenses and 6440 treatments were enrolled in the year 2018, based on a news release from the "Drug Regulatory Authority of Pakistan" (DRAP) on January 15th, 2019 (van Grootheest et al., 2004). Pakistan also contains a wide variety of medicinal herbs used to treat various diseases (Jordan et al., 2010). Herbal preparations are produced, labeled goods that include psychoactive chemicals, plant products, or a mix of therapeutic herbs (WHO, 2004). The profitability of the botanical sector is growing daily, along with the increase in the need for standard treatment (van Grootheest et al., 2004).
Srilanka
Heating and cooling herbs are classified into two groups based on physiological reactions upon consumption (Garashi et al., 2022). Application-wise, the 'cooling' herbs are administered to patients contracted with diabetes, imbalances in the lipid profile, or even cancer (Jordan et al., 2010). Modern Western medicine considers the balance between oxidation and antioxidation as critical for maintaining a healthy biological system (Williamson E, 2003). Locals can consume these herbs without the advice of a traditional medicinal practitioner, as they are familiar with these herbs.  Scientific progress has yet to be been applied to a thorough study of Sri Lanka's conventional healthcare system (Health Canada, 2006).
Nepal
Accreditation, Clinical trials, and quality control for herbal medications are now required in developed countries due to their growing popularity of using them as nutritional supplements (Gardiner et al., 2008). The government of Nepal proposed Department for Ayurvedic Medicine was presented proposed by the government of Nepal. It is time to change the widespread perception that Ayurvedic medicines have no adverse pharmacological reactions (Che et al., 2013). ADR associated with Ayurvedic medicines must be reported systematically, spontaneously, and sensibly to Ayurvedic treatments must be written systematically, spontaneously, and sensibly to generate alerts and create new scientific directions (van Grootheest et al., 2004).
Brazil
Both the National Policy of Integrative and Complementary Activities (PNPIC) and the National Policy of Medicinal Plants and Herbal Medicines (PNPMF) under the Brazilian Unified Health System (SUS) were first introduced in 2006 (Skalli et al., 2022). Analyses of the herbal remedies sector in Brazil are carried out by the individual state municipalities of the States and Municipalities, while the Brazilian Health Surveillance System, led by ANVISA, is in charge of evaluating the medicinal herbs industry there (WHO,1973). Consequently, these two laws regulate the manufacture of herbal medicines and the licensing and oversight of core plant sources' advertising, handling, dispensing, and transportation of core plant sources (Brasil, 1999) (WHO, 2000). The standard herbal medication registration has been updated to meet the needs of both PNPMF and PNPIC and to include alternate methods of ensuring the safety of medicinal herbs (Atherton et al., 1993).
South Africa
To ensure that traditional medicines are readily available, affordable for the poor, of high quality, and practical without compromising the safety of the public, in addition, to promoting the therapeutic use of herbal remedies for the customer, the WHO encourages African member states to support and incorporate folk medicine into to their healthcare systems (WHO,1973). Additionally, conventional healers and practitioners must acquire training and education to enhance the production and prescription of their herbal goods and improve their production and prescription of production and medicine of their herbal goods; conventional healers and specialists should undergo training and education (Williamson E, 2003). 


Namibia
The product's species name, registered trademarks or ingredient names, country of origin, batch number, expiration date, and supplier must all be reported (dropper) (Farah et al., 2006). Herbal medicines are now on sale and are being watched for safety as part of the current clinical study process (Williamson E, 2003). The yellow safety form paperwork noted the potential adverse effects of herbal medication negative effects of herbal medicines are pointed out in the yellow safety form paperwork (Gardiner et al., 2018). For the paperwork, VigiFlow is employed as directed by the WHO-UMC international authority. The Safety Yellow Form, the standardized reporting version, must always be accessible at primary healthcare locations, such as hospitals and clinics. 
Workflow of Pharmacovigilance
PV works the data collection of the case reports in the PV centers, and after signal detection, verification, and case assessment, the regulatory authorities either consult the WHO for the decision-making process or drug withdrawal from the market by the pharmaceutical unit (WHO, 2000).  PV targets the population affected by adverse drug events by changing dose formulations at the genetic engineering level, Immunopathy level, decreasing the toxic level within a significant range.[Fig:4].

Fig 4: Working of Pharmacovigilance 
Additionally, PV lowers the budgetary expenses of treating a patient with these issues (Fornasier et al., 2018). FDA advises the maker to construct a chance assessment that forecasts the accumulation that will be present in the environment when a new medication is prepared for market release (WHO, 2000). The medicine is fake to have moderate hazards if the risk analysis predicted that the dosage would be less than just part per billion (Rahman et al., 2007).
Conclusion
Drug safety is essential to the medical sector in every country. Around the world, regulatory agencies in various nations keep an eye on all drugs' effectiveness and clinical governance full effectiveness and clinical management of all medications drugs as they circulate. Not only do herbal medicines need effective regulation, but they also require raising the attention of drug administration, pharmacology, and adverse drug reactions. This review study closely adheres to the WHO recommendations and acknowledges the information and data from the Uppsala Monitoring Centre (UMC). Regulatory organizations take the patient's health into account patient's patient's health is taken into account by regulatory organizations at every step, from the narrative of how PV and HV have progressed through changes in the laws controlling medication adherence and surveillance worldwide.
References
Atherton, D. J., Rustin, M. H., & Brostoff, J. (1993). Need for correct identification of herbs in herbal poisoning. Lancet (London, England), 341(8845), 637–638.
Biswas, P., Biswas, A. (2007). Setting standards for proactive pharmacovigilance in India: The way forward. Indian journal of  pharmacology,39,124–8. 
Che, C. T., Wang, Z. J., Chow, M. S., & Lam, C. W. (2013). Herb-herb combination for therapeutic enhancement and advancement: theory, practice and future perspectives. Molecules (Basel, Switzerland), 18(5), 5125–5141. 
Farah, M. H., Edwards, R., Lindquist, M., Leon, C., & Shaw, D. (2000). International monitoring of adverse health effects associated with herbal medicines. Pharmacoepidemiology and drug safety, 9(2), 105–112. 
Farah, M. H., Olsson, S., Bate, J., Lindquist, M., Edwards, R., Simmonds, M. S., Leon, C., de Boer, H. J., & Thulin, M. (2006). Botanical nomenclature in pharmacovigilance and a recommendation for standardisation. Drug safety, 29(11), 1023–1029. 
Fornasier, G., Francescon, S., Leone, R., & Baldo, P. (2018). An historical overview over Pharmacovigilance. International journal of clinical pharmacy, 40(4), 744–747. 
Garashi, H. Y., Steinke, D. T., & Schafheutle, E. I. (2022). A Systematic Review of Pharmacovigilance Systems in Developing Countries Using the WHO Pharmacovigilance Indicators. Therapeutic innovation & regulatory science, 56(5), 717–743. 
Gardiner, P., Sarma, D. N., Low Dog, T., Barrett, M. L., Chavez, M. L., Ko, R., Mahady, G. B., Marles, R. J., Pellicore, L. S., & Giancaspro, G. I. (2008). The state of dietary supplement adverse event reporting in the United States. Pharmacoepidemiology and drug safety, 17(10), 962–970.  
Harmark, L., & van Grootheest, A. C. (2008). Pharmacovigilance: methods, recent developments and future perspectives. European journal of clinical pharmacology, 64(8), 743–752. 
Health Canada, 2006. Reporting adverse reactions for naturopathic doctors. 
Health Canada, 2009a. Release of the guidance document for industry - reporting adverse reactions to marketed health products. 2009. 
Hinder, M., Hartl, D.  (2022). Translational Medicine – The Bridging Discipline. Role and Tools in the Drug Development Process. Principles of Biomedical Sciences and Industry,119-138,
Jordan, S. A., Cunningham, D. G., & Marles, R. J. (2010). Assessment of herbal medicinal products: challenges, and opportunities to increase the knowledge base for safety assessment. Toxicology and applied pharmacology, 243(2), 198–216.  
Public Health Agency of Canada (2022). Public Health Practice. Retrieved from https://www.canada.ca/en/public-health/services/public-health-practice/surveillance.htm
Rahman, S. Z., Khan, R. A., Gupta, V., & Uddin, M. (2007). Pharmacoenvironmentology--a component of pharmacovigilance. Environmental health: a global access science source, 6, 20.
Shetti, S., Kumar, C. D., Sriwastava, N. K., & Sharma, I. P. (2011). Pharmacovigilance of herbal medicines: Current state and future directions. Pharmacognosy magazine, 7(25), 69–73.
Skalli, S., Wang, J., Hugman, B. (2022). Chapter 9 - Pharmacovigilance of herbal medicines: The vigilance of tomorrow, Editor(s): Pulok K. Mukherjee, Evidence-Based Validation of Herbal Medicine (Second Edition), Elsevier, 2022, Pages 239-250, ISBN 9780323855426
van Grootheest, K., Olsson, S., Couper, M., & de Jong-van den Berg, L. (2004). Pharmacists' role in reporting adverse drug reactions in an international perspective. Pharmacoepidemiology and drug safety, 13(7), 457–464. 
Wal, P., Wal, A., Gupta, S., Sharma, G., & Rai, A. (2011). Pharmacovigilance of herbal products in India. Journal of young pharmacists: JYP, 3(3), 256–258. 
WHO Policy Perspectives on Medicines. Geneva: WHO; 2004. Geneva: World Health Organization. Looking at the Pharmacovigilance: ensuring the safe use of medicines. 
WHO. (2004). WHO guidelines on safety monitoring of herbal medicines in pharmacovigilance systems. Retrieved from https://apps.who.int/iris/bitstream/handle/10665/43034/9241592214_eng.pdf
Williamson E. M. (2003). Drug interactions between herbal and prescription medicines. Drug safety, 26(15), 1075–1092. 
World Health Organization. (‎1973)‎. Handbook of resolutions and decisions of the World Health Assembly and the Executive Board, v. 1: cumulative definitive ed.; v. 2: cumulative definitive ed.; v. 3: 3rd ed. World Health Organization. Retrieved from https://apps.who.int/iris/handle/10665/79012
World Health Organization. (‎2000)‎. WHO medicines strategy : framework for action in Essential Drugs and Medicines Policy 2000-2003. World Health Organization. Retrieved from https://apps.who.int/iris/handle/10665/66503
World Health Organization. (‎2002)‎. The importance of pharmacovigilance. World Health Organization. Retrieved from https://apps.who.int/iris/handle/10665/42493